Blood cancer Archives

frits ahlefeldt cellectis servier pfizer ucart leukemia1

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis's leading product UCART19 for…

November 19, 2015 - 3 minutesmins - By Dani Bancroft

diatoms neuroblastoma chemotherapy algae TUdresden biocube

News and Trends 11 Nov 2015

Using Algae and NanoTech to Kill Cancer: An Australian-German Collaboration

Algae diatoms are now being used to kill cancer! A new research paper on nano-particles from Adelaide (Australia) has worked with researchers at the Dresden University of Technology (TUD) to…

November 11, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 11 Nov 2015

French-Danish Clinical Trial Made Blood Cancer Disappear in 72% of Patients

Onxeo is the French orphan-drug specialist in Oncology who has various pipelines for certain cancers. Now their phase I clinical trial of belinostat (trade name Beleodaq) combined with chemo for…

November 11, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 29 Oct 2015

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

Cellectis is a leader in immuno-oncology CAR-T therapies from France, which might revolutionise cancer treatments. Now, the next step in the CAR-T campaign is to step away from personalised (autologous)…

October 29, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 22 Oct 2015

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Lyon's Erytech (France) is a clinical biopharma working on improving its red blood cell transported drug, targeting cancers such as acute lymphocytic leukemia (ALL) and pancreatic adenocarcinoma. Now phase I/II…

October 22, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Oct 2015

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin's Lymphoma. An undisclosed shareholder has just increased its…

October 19, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 13 Oct 2015

Why can’t Novartis Commit to the Israeli Biotech Scene?

Novartis, the Swiss Acquisition-Giant from Basel, has once again taken bought a small chunk of shares from the Israel biotech scene for only $15M (2.5%), instead of making a final…

October 13, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

A pioneering CAR-T cell therapy study from Novartis and the University of Pennsylvania demonstrates the impressive potential of the next-generation therapy. Five years after the start of the study, three…

September 4, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

18-year-old French Hybrigenics goes to the US with its Acute Myeloid Leukemia Treatment

Hybrigenics is one step closer to enter the American market. The FDA granted Orphan Drug designation to the company's Acute Myeloid Leukemia (AML) Treatment. Currently in preclinical stage, the therapy…

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been…

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from…

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 8 Jul 2015

Genmab and Novartis look for the European approval of their leukemia candidate

Genmab is seeking the European authorization for Arzerra, a treatment co-developed with Novartis. The submission is based on the candidate’s positive results in its Phase III in patients with leukemia.…

July 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Jun 2015

Innovate UK accelerates Sareum’s fight against Leukemia

Innovate UK, the country’s innovation agency, keeps promoting technology in the British islands. The latest beneficiary is Sareum, a cancer specialist biotech with a strong autoimmune disease programme. The company…

June 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jun 2015

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Genmab and its partner Jonhson&Jonhson, through its subsidiary Janssen Biotech, are trying to speed up daratumumab. The companies initiated a rolling submission for the candidate that targets multiple myeloma. The…

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Jun 2015

Novartis declines Gamida’s buyout deal for the second time

Novartis has rejected the Israeli biotech Gamida Cell… again. The Big Pharma has decided not to carry out its option on the Israel-based company. The transaction would have meant a €535.5M deal…

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 4 Jun 2015

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

MorphoSys has presented at ASCO optimistic results of MOR202’s phase I/IIa study, a candidate treatment against multiple myeloma. The project was doubted after Celgene’s abandon, but now, safety and efficacy data…

June 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jun 2015

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the…

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 May 2015

Baxter’s spinoff Baxalta is building up its Oncology portfolio

Baxter has purchased Sigma-Tau’s portfolio of cancer treatments for €793.5M ($900 million). With this important acquisition, Baxter is reinforcing its oncology presence by owning Oncaspar, a treatment against acute lymphocytic…

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

TEVA Eagle Pharmaceuticals leukemia bendamustine

News and Trends 17 Apr 2015

Teva took the first step to get the approval of its new leukemia treatment

FDA accepted Teva Pharma’s New Drug Application (NDA) for a liquid bendamustine hydrochloride (HCl) rapid infusion product. The drug, developed with Eagle Pharmaceuticals is now waiting for the Prescription Drug…

April 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Feb 2015

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the…

February 22, 2015 - 3 minutesmins - By Joachim Eeckhout

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Register for the Webinar

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering